Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover

Abstract

Background:The recent SARS-CoV-2 pandemic, which has recently affected Italy since February 21, constitutes a threat to normal subjects, as the coronavirus disease-19 can manifest with a broad spectrum of clinical phenotypes ranging from asymptomatic cases to pneumonia or even death. There is evidence that older age and several comorbidities can affect the risk to develop severe pneumonia and possibly the need of mechanic ventilation in subjects infected with SARS-CoV-2.Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA). Methods:When the SARS-CoV-2 epidemic has reached Italy, we have activated a surveillance protocol of patients with IEI, to perform SARS-CoV-2 search by nasopharyngeal swab in patients presenting with symptoms that could be a manifestation of COVID-19, such as fever, cough, diarrhea, or vomiting. Results:We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions. Both patients developed interstitial pneumonia characterized by fever, cough, and anorexia and associated with elevation of CRP and ferritin, but have never required oxygen ventilation or intensive care. Conclusion:Our report suggests that XLA patients might present with high risk to develop pneumonia after SARS-CoV-2 infection, but can recover from infection, suggesting that B-cell response might be important, but is not strictly required to overcome the disease. However, there is a need for larger observational studies to extend these conclusions to other patients with similar genetic immune defects. K E Y W O R D S BTK, immunoglobulins, SARS-CoV-2, X linked agammaglobulinemia How to cite this article: Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020;00:1-5. https://doi.

Currently Available Intravenous Immunoglobulin Contains Antibodies Reacting Against Severe Acute Respiratory Syndrome Coronavirus 2 Antigens

“…When considered together, these immunomodulatory effects of IVIG products might be beneficial in COVID-19 disease management, but this needs to be confirmed clinically. Although IVIG may not confer protection against SARS-CoV-2, the role of antibodies crossreacting with SARS-Cov-2 has been suggested by exerting a priming effect on host immune response or through an immunomodulatory action on monocytes and tissue-resident macrophages [25]. The antibody-dependent enhancement (ADE) phenomenon associated with non-neutralizing antiviral proteins in IVIG also needs to be considered.…”

The first, holistic immunological model of COVID‐19: Implications for prevention, diagnosis, and public health measures

“…75 Both patients developed pneumonia, and both recovered without any need of receiving oxygen therapy. 75 In another Italian study, the clinical course of COVID-19…”

“…This hypothesis may contribute to explain why patients with agammaglobulinemia had a mild pneumonia and recovered without experiencing complications requiring oxygen therapy. 75 Antibodies may be simply a consequence of a powerful viral replication, or rather the direct trigger of a severe inflammation. This may be explained with different mechanisms:…”

Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T cell memory formation after mild COVID-19 infection

“…The T cell response was shown to be critical for protection in SARS-1-infected mice [6]. Patients with X-linked agammaglobulinemia, a genetic disorder associated with lack of B cells, have been reported to recover from symptomatic COVID-19 [7,8], suggesting that in some cases T cells are sufficient for viral clearance. Theravajan et al showed that activated CD8+HLA-DR+CD38+ T cells in a mild case of COVID-19 significantly expand following symptom onset, reaching their peak frequency of 12% of CD8+ T cells on day 9 after symptom onset, and contract thereafter [9].…”